Given all the reasons that growth of the contrast media market could have flattened dramatically by now, its rise to about $3.5 billion in worldwide sales last year is remarkable. Once projected to reach $5.5 billion by 1995 (the market was one-tenth that size in 1985), about $1 billion of the 1995 estimate was expected to materialize through the introduction and growth of MRI and ultrasound agents. But only one ultrasound agent, Molecular Biosystems Inc. ’s Albunex, has been approved in the US and sales of MRI agents have grown to only a third of the $900 million projected for 1995.
Driving the growth over the past decade has been the expanded use of low-osmolar, non-ionic contrast agents across a broad...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?